EUVIMEDEUVIMED entdecken
Crossref

A Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy

Jiawei Liu, Jingwen Zhang, Shihao Song, Xinmin Zhang, Feng Lu iD, Meixing Li iD, Shanshan Wang, Qi Wang iD, Tangxin Xiao iD

Chemistry – A European Journal · 09.11.2026

DOI: 10.1002/chem.71891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, online erschienen am 09.11.2026. Verfasst von Jiawei Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjin…. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Huali Talents Program of Nanjing University of Posts and Telecommunications, China Postdoctoral Science Foundation, Nationally Funded Postdoctoral Researcher Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia, as a unique tumor microenvironment, offers an opportunity for the development of activatable therapeutic agents. However, most current activatable agents are confined to monotherapy, limiting their overall efficacy. We herein report a novel single‐molecule prodrug for hypoxia‐activated trimodal cancer therapy. A diketopyrrolopyrrole‐based molecule ( AMO ) was first synthesized, demonstrating efficient type‐I photodynamic (PDT) and photothermal (PTT) activities. To integrate chemotherapy, a hypoxia‐cleavable azo linker was introduced to conjugate a cytotoxic drug, nitrogen mustard, yielding the prodrug AIO . Under normoxic conditions, the AIO exhibited attenuated phototherapeutic effects, minimizing off‐target toxicity. In contrast, the hypoxic tumor environment triggered azo cleavage, releasing the chemotherapeutic agent while simultaneously restoring type‐I PDT and PTT functionalities. This work provides an activatable trimodal combination therapeutic strategy with promising translational potential for precise cancer treatment.

Schlagwörter

Stichwörter der Autor:innen

activatablecombination therapyhypoxiasingle‐molecule prodrugtype‐I photodynamic therapy

Autor:innen und Institutionen

  • State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, China.
  • Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Petrochemical Engineering, Changzhou University, Changzhou, China.

ORCID-Profile: Feng Lu, Meixing Li, Qi Wang, Tangxin Xiao

Förderung

  • Huali Talents Program of Nanjing University of Posts and Telecommunications
  • China Postdoctoral Science Foundation
  • Nationally Funded Postdoctoral Researcher Program

Zitieren

APA

Liu, J., Zhang, J., Song, S., Zhang, X., Lu, F., Li, M., Wang, S., Wang, Q., & Xiao, T. (2026). A Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy. Chemistry – A European Journal. https://doi.org/10.1002/chem.71891

Vancouver

Liu J, Zhang J, Song S, Zhang X, Lu F, Li M, et al. A Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy. Chemistry – A European Journal. 2026. doi:10.1002/chem.71891

BibTeX
@article{Liu2026,
  author = {Liu, Jiawei and Zhang, Jingwen and Song, Shihao and Zhang, Xinmin and Lu, Feng and Li, Meixing and Wang, Shanshan and Wang, Qi and Xiao, Tangxin},
  title = {A Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy},
  journal = {Chemistry – A European Journal},
  year = {2026},
  doi = {10.1002/chem.71891}
}
Kostenlos starten →